Pharmacy Daily | Views on LVT model mixed

SUBMISSIONS to the Therapeutic Goods Administration’s (TGA) consultation on the Low Value Turnover exemption (LVT) scheme are mixed as to what it should look like going forward. The scheme allowed sponsors to seek an exemption from payment of annual Australian Register of Therapeutic Goods charges for entries with low value turnover but predated the National Medicines Policy and had had complaints about administrative burden, the TGA said. Symbion Pharmacy Services said it was “okay” with retaining the current LVT scheme form but would prefer efficiency improvements. Both GlaxoSmithKline (GSK) and Sanofi ANZ supported replacing the scheme with one that granted exemptions only for Register entries which were not supplied to the Australian market, with GSK saying this would reduce the administrative burden, simplify criteria for eligibility and improve efficiency, and was justified since only goods which required post market monitoring would be required to pay annual fees. The Complementary Healthcare Council said it supported retaining the scheme with some amendments to help small to medium sized businesses with a “better targeted and lower burden scheme”. The Australian Self Medication Industry suggested alternative approaches to streamlining the process including radio buttons to indicate whether a product

---

The above article was sent to subscribers in Pharmacy Daily's issue from 29 Aug 14
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Aug 14